BCL2 and acute myeloid leukemia: This is not surprising, given the fact that the expression of BCL2 is differentiation stage specific, being at its highest in immature myeloid progenitors, and decreasing at the final stages of differentiation.35 This finding is very important when anti-BCL2 therapy (venetoclax) is used in the treatment of AML.